Co. Tipperary based Shorla acquires cancer drug Jylamvo

The pharmaceutical business has purchased the drug rights from Therakind

Orlaith Ryan and Sharon Cunningham, co-founders of Shorla, recently raised $35 million in funding. Picture: file

Shorla Oncology, a Tipperary based company, has acquired the oncology and autoimmune drug Jylamvo from Therakind for sale on the US market.

The drug can be used to treat a number of conditions and is designed to avoid the need to split or crush pills.

Susan Conroy, chief executive officer of UK company Therakind, said in a statement: “Therakind is pleased that Jylamvo will now become available to patients in the United States providing a ...